Home announce collaboration
 

Keywords :   


Tag: announce collaboration

Immunocore And Lilly Announce Immunotherapy-Based Clinical Trial Collaboration In Melanoma

2015-07-01 08:13:50| drugdiscoveryonline Home Page

Immunocore Limited and Eli Lilly and Company recently announced that they have entered into an immunotherapy-based clinical trial collaboration to explore the utility of Immunocore’s lead T-cell receptor based investigational therapeutic, IMCgp100, in combination with Lilly’s galunisertib (LY2157299) and merestinib (LY2801653) for the treatment of melanoma

Tags: trial clinical collaboration announce

 

Celgene and Juno Announce Ten-Year Collaboration to Advance...

2015-06-29 23:23:19| Biotech - Topix.net

Broad strategic collaboration leveraging combined immunology expertise and assets to develop and commercialize novel immunotherapies for the treatment of cancer and autoimmune diseases Celgene to make initial payment of approximately $1 billion which includes the purchase of ~9.1 million shares of Juno stock at $93.00 per share, with potential to increase its stake over time SUMMIT, N.J. & SEATTLE-- -- Celgene Corporation and Juno Therapeutics, Inc. announced today a global collaboration for the development and commercialization of immunotherapies.

Tags: advance collaboration announce juno

 
 

Soitec And Shanghai Industrial Technology Research Institute (SITRI) Announce Collaboration On High-Performance RF-SOI Technology

2015-06-09 08:09:48| rfglobalnet Home Page

Soitec, a world leader in generating and manufacturing revolutionary semiconductor materials for the electronics and energy industries, and Shanghai Industrial µTechnology Research Institute (SITRI), a leader in “More than Moore” technology R&D and commercialization, announced recently the signature of a collaboration agreement.

Tags: research technology industrial institute

 

Merck and Dynavax Announce New Collaboration Investigating the Combination of Immuno-Oncology Therapies

2015-06-01 14:30:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. & BERKELEY, Calif. Studies to Evaluate the Combination of Dynavaxs SD-101 with Two Immunotherapies from Mercks Pipeline, KEYTRUDA (pembrolizumab) and MK-1966 Collaboration Includes First-in-human Study for MK-1966, a New Investigational Anti-interleukin-10 (anti-IL-10) Immunomodulator from Mercks Rapidly Growing Immuno-oncology Pipeline KENILWORTH, N.J. Language: English Contact: Merck Media Relations:Pamela Eisele, 267-664-0282Claire Mulhearn, 908-200-1889orMerck Investor Relations:Justin Holko, 908-740-1879orDynavax Investor/Media Relations:Michael Ostrach, 510-665-7257 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: combination collaboration announce investigating

 

Amgen and Merck Announce Expansion of Collaboration to Support Studies of Talimogene Laherparepvec in Combination with KEYTRUDA (pembrolizumab) in Patients with Head and Neck Cancer

2015-05-29 14:30:32| Merck.com - Product News

Dateline City: THOUSAND OAKS, Calif. and KENILWORTH, N.J. Companies Also Plan to Initiate Phase 3 Trial in Combination for Advanced Melanoma THOUSAND OAKS, Calif. and KENILWORTH, N.J., - May 29, 2015 Amgen (NASDAQ: AMGN) and Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, today announced an expanded collaboration to evaluate the efficacy and safety of talimogene laherparepvec, Amgens investigational oncolytic immunotherapy, in combination with KEYTRUDA (pembrolizumab), Mercks anti-PD-1 therapy, in a Phase 1, open-label trial of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Language: English read more

Tags: with support head studies

 

Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] next »